{"date":"2025-03-02","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6589-2025-03-02-1627-1e8scm1","company_id":"6589","company":"台康生技","market":"上市","industry":"生技醫療","date":"2025-03-02","time":"16:27:32","subject":"本公司研發中產品EG1206A（pertuzumab生物相似藥）第三期臨床試驗計畫書已成功送交衛生福利部食品藥物管理署(TFDA)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：台康生技（6589），2025-03-02 16:27，「本公司研發中產品EG1206A（pertuzumab生物相似藥）第三期臨床試驗計畫書已成功送交衛生福利部食品藥物管理署(」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}